Skip to main content
CRDF logo

CRDF · Cardiff Oncology, Inc.

Track CRDF — free
$0.87 +0.14 (+19.31%)
Market Cap
$56.49M
Shares
77.80M
Volume · Nov 16 15.06M Avg daily vol (3M) 591.25K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.73 Open$0.73 Day$0.71–0.74 52W close$0.73–3.21 Avg vol 30d393K Short int12.3M · 15.8% of shares · 30.8d Short vol56% Last earningsNov 12, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 12

Up next

Jun 2, 2027 Est · unconfirmed · in 28 wks
call held Feb 27, 2025

Latest documents

2026
Nov 12
Current report 8-K Events of Nov 10
Onvansertib Phase 3 start potential in Q1 2027

Cardiff Oncology reported that median PFS has not been reached in the 30 mg onvansertib + FOLFIRI/bev arm versus approximately 11 months in combined standard-of-care arms. It is preparing a registrational Phase 3 trial with a potential Q1 2027 start.

Financial results
3 source passages
SAN DIEGO, Calif., November 12, 2026 — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced financial results for the third quarter ended September 30, 2026, and provided a business update. Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms Company preparing for registrational Phase 3 trial in first-line RAS-mutated mCRC, with potential start in Q1 2027 Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Onvansertib achieved 72.2% response rate in first-line mCRC

Cardiff Oncology said onvansertib plus FOLFIRI/bev achieved a 72.2% confirmed objective response rate versus 42.1% for FOLFIRI/bev alone in first-line RAS-mutated mCRC, a 30 percentage point improvement. It plans a global Phase 3 trial enrolling approximately 640 patients.

Read from the MD&A section
3 source passages
Primary endpoint of confirmed objective response rate of 72.2% (13/18), compared with 42.1% (8/19) for FOLFIRI/bev alone, a 30 percentage point improvement over SoC. We have designed the registrational Phase 3 trial (CRDF-005) as a global randomized, controlled trial that will evaluate the safety and efficacy of onvansertib 30 mg + FOLFIRI/bev versus SoC FOLFIRI/bev as first-line therapy in patients with RAS-mutated mCRC. We expect to enroll approximately 640 patients across sites in the US, Europe and other regions. CARDIFF ONCOLOGY, INC. Open the document at this passage
Oct 22
Current report 8-K
Shareholder vote results

Cardiff Oncology stockholders approved increasing authorized capital stock from 170,000,000 to 320,000,000 and authorized common stock from 150,000,000 to 300,000,000 at the October 22, 2026 Special Meeting.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$559,000
Trailing 12 months
Net income (TTM)
−$37.65M
Trailing 12 months
Revenue growth YoY
+42.5%
Year over year
Operating margin
-7,068.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$33.79M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+13.9%
Year over year · more shares
Price change (1Y)
-66.2%
Trailing year
Short interest
15.8%
Latest settlement · 30.8 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −46%
below
Price vs 50-day avg −30%
below
RSI (14) 31
neutral
MACD trend Negative
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −19%
trailing
6-month return −63%
trailing
YTD return −74%
this year
Relative strength −63%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
84 of 105 funds reported for Sep 30 · net -1.4M sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
15.76% of shares out · ▲ +1.2% MoM · 30.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
105 holders — mid 3-yr range
Squeeze score 74
high risk · 0–100
Fundamentals
Strong
Revenue growth +50%
Y/Y
EPS growth +27%
Y/Y
Free cash flow $-38.0M
Balance sheet $17.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 88%
annualized · 1-yr
Max drawdown −77%
past year
ATR 9.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−46% Bearish
Price vs 50-day avg
−30% Bearish
RSI (14)
31 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
84 of 105 funds reported for Sep 30 · net -1.4M sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
15.76% of shares out · ▲ +1.2% MoM · 30.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
105 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $3
vs 200-day avg -46% vs 50-day avg -30%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CRDF
Cardiff Oncology, Inc.
this stock
$56.49M -74.2% +49.6% — 15.8%
VRTX
Vertex Pharmaceuticals Inc
$136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
$90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
$66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
85
% held
22.3%
Reported
84 of 105
Top holder
Laurion Capital Managemen…
Held Float
View
Held by Funds
Fund positions
25
View
Short & Settlement
Short Interest Rising
Shares short
12.3M
Days to cover
30.8d
Change
+143.0K sh
View
Short Volume
Short vol %
56%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
199
Value
$181
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
56.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$593.0K
Net income (FY)
$-45.9M
EPS diluted
$-0.69
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 12, 2026
This year
29

Cardiff Oncology said onvansertib plus FOLFIRI/bev achieved a 72.2% confirmed objective response rate versus 42.1% for FOLFIRI/bev alone in first-line RAS-mutated mCRC, a 30 percentage point improvement. It plans a global Phase 3 trial enrolling approximately 640 patients.

View
Exempt Offerings
Offering
$13.5M
Filed
Jun 23, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 16, 2026
View
Investor Relations
Latest news
Cardiff Oncology Reports Third Qu…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
CRDF -8.7% -19.4% -62.6% -18.4% -74.2%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -11.3% -18.3% -63.1% -18.2% -84.8%
Key facts CIK 1213037 CUSIP 14147L108 13F (30d) 63 filings 52 filers Visit website Investor relations